ENLV macrophage reprogramming

Enlivex is a very interesting Israeli company.  Their cell therapy allocetra is effective against cytokine storm.  The big money is of course as a treatment for sepsis, but they are quickly advancing in trials for covid as well and guide that they could be granted emergency use status as early as this quarter in Europe.  The technology is simple, elegant, and brilliant.  What they do is produce a culture of early apoptotic cells (cells that are programmed to commit suicide) and transfuse them into a patient.  When the bodies' macrophages eat apoptotic cells, the macrophages subsequently send out calming signals; this stops cytokine storm dead in its tracks.  The preliminary data looks near miraculous, 0% mortality and patients who typically stay in the hospital for over a month are going home in a week.  Macrophages can be reprogrammed similarly to become more active, this allows them to potentially treat a whole host of other indications such as cancer.  They have some interesting pre-clinical studies where they use allocetra as a bolt-on treatment to PLD-1 kind of like oncosec does with very good results.  The cancer stuff is a long way off, but interesting none the less, as it really shows how innovative and paradigm changing of a technology they have with macrophage reprogramming.  The company is well funded 90M and low burn rate as well as low float.  Market cap is sitting at a paltry quarter billion.  Their cell product is derived from blood donations.  When blood is donated they spin out the WBC and typically throw those away, instead Enlivex generates allocetra from that former waste product.